whatshot

DSRLF   $107.0  -10.08% Market Closed

DiaSorin SpA
show_chart Advanced Chart of DSRLF
Last Events:

2022-09-23 Trend pattern changed from симметричный треугольник to нисходящий треугольник.

2022-09-23 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2022-09-23 Signal in EMA50 changed from n/a to bearish reversal. 2022-01-06 the price crossed down the moving average line and formed a short-term downside trend.

2022-09-23 Trend Power changed from slow to strong.

2022-09-23 Trend changed from flat and down to turning down.

2022-08-24 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2022-08-24 Signal in EMA50 changed from bearish reversal to n/a. 2021-03-15 the price crossed down the moving average line and demonstrates a downside trend.

2022-08-24 Trend changed from turning down to flat and down.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 14
Target Price Mean 109
Mean unverified/preliminary 109 / 109
Target Price Low / High 83 / 129
Median / STD DEV 114 / 15.02
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Buy -
rsi ActivelyBuy - -
macd Sell Buy -
stoch Sell - -
ma20 Sell - -
ma50 Sell - -
ma100 Sell - -
ISIN IT0003492391
ceo Mr. Carlo Rosa
Website https://diasoringroup.com/en
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.